Metal Drugs for Multimodal Applications

Christine O’Connor  
*Technological University Dublin*

Luke O’Neill  
*Dublin Institute of Technology*

Laura Perdisatt  
*Dublin Institute of Technology*

Samar Moqadasi  
*Dublin Institute of Technology*

Alan Casey  
*Dublin Institute of Technology*

See next page for additional authors

Follow this and additional works at: https://arrow.dit.ie/schfsehcon

Recommended Citation

This Conference Paper is brought to you for free and open access by the School of Food Science and Environmental Health at ARROW@TU Dublin. It has been accepted for inclusion in Conference papers by an authorized administrator of ARROW@TU Dublin. For more information, please contact yvonne.desmond@dit.ie, arrow.admin@dit.ie, brian.widdis@dit.ie.

This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 3.0 License
Over the past decade a structured synthetic approach to the design and development of Ruthenium (II) polypyridyl complexes has been carried out at the DIT. Initial studies commenced with the design and synthesis of the ligands and the complexes themselves in the form of $[\text{Ru(L}_1\text{L}_2^2]^2^+$, where $\text{L}_1$ is 2,2'-bipyridine, 1, 10-phenanthroline or 2,2'-biquinoline and $\text{L}_2$ is the main ligand with varying electronegativity properties. Ru (II) complexes are known to mimic iron in biological media and are really coming to the forefront in areas such as anticancer and antimicrobial applications. The photophysical characterisation of the complexes has been studied to determine a mechanism for optimising the luminescent yield and lifetimes of the complexes with the view of light activation applications in the future. The regioisomer complexes of the $\text{L}_2$ ligand and DNA intercalation studies were also carried out. More recently the biological evaluation has commenced of the complexes and some promising results have been observed against certain cell lines. The most promising candidates have shown ROS activity, selectivity for A549 cell lines and activity against two strains of yeast cells ($\text{Saccharomyces cerevisiae}$) wild type (BY4741) and a deficient strain in superoxide dismutase 1 (sod1). At present the complexes are undergoing further mechanistic studies to determine their mode of action. In parallel to this work the complexes are also being investigated for their potential antimicrobial behaviour.

References